Pharmacokinetics and dosing estimation of meropenem in Japanese patients receiving continuous venovenous hemodialysis

Shinji Kawano, Kazuaki Matsumoto, Ryohei Hara, Yuko Kuroda, Kazuro Ikawa, Norifumi Morikawa, Tetsuya Horino, Seiji Hori, Junko Kizu

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The pharmacokinetics of meropenem have not yet been examined in Japanese patients receiving Continuous venovenous hemodialysis (CVVHD). The aim of this clinical investigation was to determine the pharmacokinetic parameters of meropenem in critically ill patients receiving CVVHD in order to estimate dosing regimens for the patient population in Japan. The values of pharmacokinetic parameters were 17.5±5.6l for V<inf>1</inf>, 1.27±0.38h<sup>-1</sup> for K<inf>12</inf>, 0.71±0.40h<sup>-1</sup> for K<inf>21</inf> and 0.17±0.02h<sup>-1</sup> for K<inf>10</inf>. Based on these mean parameters (V<inf>1</inf>, K<inf>12</inf>, K<inf>21</inf> and K<inf>10</inf>), time above MIC (T>MIC) values were estimated at different MICs using various meropenem regimens. For bacteria with a meropenem MIC of ≤2μg/ml, a dosing regimen of 0.25g every 24h achieved more than 40% T>MIC. For a MIC of 4μg/ml, all the regimens tested, except for 0.25g every 24h, achieved more than 40% T>MIC. For a MIC of 16μg/ml, dosing regimens of 0.5g every 8h, 1g every 12h, and 1g every 8h achieved 40% T>MIC, reaching the pharmacokinetic-pharmacodynamic target range. This is the first study to examine the pharmacokinetics of meropenem under a CVVHD setting in Japan. The pharmacokinetic-pharmacodynamic profile of dosing regimens tested in this study will assist in selecting the appropriate meropenem regimens for patients receiving CVVHD.

Original languageEnglish
Pages (from-to)476-478
Number of pages3
JournalJournal of Infection and Chemotherapy
Volume21
Issue number6
DOIs
Publication statusPublished - 2015 Jun 1

Keywords

  • Continuous venovenous hemodialysis
  • Dosing regimen
  • Meropenem
  • Pharmacokinetics

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Pharmacokinetics and dosing estimation of meropenem in Japanese patients receiving continuous venovenous hemodialysis'. Together they form a unique fingerprint.

  • Cite this